DivestmentMay 5, 2026, 05:12 PM
Cumberland to divest branded portfolio for $100M; Q1 Net Loss $3.3M
AI Summary
Cumberland Pharmaceuticals announced a strategic transaction to divest its portfolio of FDA-approved brands to Apotex Inc. for $100 million in cash, aiming to sharpen its focus on developing high-value product candidates. For the first quarter of 2026, the company reported net revenues of $9.1 million and a net loss of $3.3 million. Additionally, Cumberland provided updates on its development pipeline, including breakthrough Phase II results for ifetroban in Duchenne muscular dystrophy and FDA Fast Track Designation for the candidate.
Key Highlights
- Cumberland to divest its FDA-approved branded portfolio to Apotex for $100 million in cash.
- Q1 2026 net revenues were $9.1 million, a 5% increase YoY excluding a prior milestone payment.
- Reported a Q1 2026 net loss of $3.3 million, compared to a net income of $1.25 million in Q1 2025.
- Adjusted loss for Q1 2026 was $1.9 million, or $0.13 per share.
- Ended Q1 2026 with $11.0 million in cash and cash equivalents.
- Total assets were $71.0 million as of March 31, 2026.
- Ifetroban received FDA Fast Track Designation for Duchenne muscular dystrophy (DMD).
- Breakthrough Phase II clinical study results for ifetroban in DMD patients were announced.
Price Impact
More from CPIX